Medical Cannabis May Help Manage Some Mesothelioma Symptoms

Mesothelioma treatment can be physically demanding, and managing pain, nausea, appetite changes, anxiety, and sleep problems is an important part of care. Cannabis-based medicines may help some patients with selected symptoms, but current evidence does not show that cannabis treats or cures mesothelioma.

Mesothelioma is a rare cancer that develops in the mesothelium, the thin tissue surrounding organs such as the lungs, chest wall, abdomen, and heart. Asbestos exposure is its major known risk factor. Symptoms vary by location but may include shortness of breath, chest or abdominal pain, fluid buildup, fatigue, and unexplained weight loss. More information is available in the National Cancer Institute’s overview of what mesothelioma is and its common symptoms.

Depending on the type and stage of the disease, treatment may include surgery, chemotherapy, radiation therapy, immunotherapy, targeted therapy, and palliative procedures. These treatments can cause side effects, making supportive care a central part of mesothelioma management. The NCI’s mesothelioma treatment guidance describes the standard options and the role of palliative care in relieving symptoms and improving quality of life.

Cannabis and cannabinoid medicines are sometimes used as complementary treatments, particularly when conventional therapies have not adequately controlled nausea or pain. However, the evidence differs substantially by symptom and by product. Cannabis itself is not approved by the U.S. Food and Drug Administration as a cancer treatment. The FDA has approved the cannabinoid medicines dronabinol and nabilone for chemotherapy-related nausea and vomiting when standard anti-nausea medicines have not worked.

Some research suggests that cannabinoids can reduce chemotherapy-induced nausea and vomiting. Evidence for appetite improvement is less consistent: in patients with advanced cancer and loss of appetite, oral THC did not increase appetite or weight gain as effectively as the established appetite stimulant megestrol. Claims that cannabis reliably improves appetite, sleep, or anxiety in people with mesothelioma therefore go beyond what clinical research currently demonstrates.

Pain relief is also more complicated than early reports suggested. A small 2011 controlled clinical study of vaporized cannabis combined with opioids included 21 people with chronic pain, not a mesothelioma-specific group. The study found improved pain scores among participants taking morphine, but not among those taking oxycodone. Its small size and design mean the findings cannot establish that cannabis will provide the same benefit for mesothelioma-related pain.

Another frequently cited line of research involves nabiximols, an oral spray containing THC and CBD. Although earlier studies suggested possible benefit for some patients with advanced cancer pain that remained uncontrolled despite opioids, two phase 3 randomized trials did not meet their primary pain-relief endpoints. The results do not rule out benefit for every patient, but they show why cannabis-based medicines should not be described as a proven treatment for severe cancer pain. The trial is available through PubMed.

Patients considering cannabis should discuss it with their oncologist, palliative-care specialist, or pharmacist before using it. Products can cause drowsiness, dizziness, impaired concentration, low blood pressure, rapid heartbeat, anxiety, or paranoia, and some people can develop dependence. Cannabis may also interact with other medicines. Inhaled products may be especially unsuitable for people with compromised lung function, while edible products can have delayed and unpredictable effects.

The most defensible role for cannabis in mesothelioma care is as a possible symptom-management option—not as a substitute for surgery, chemotherapy, radiation, immunotherapy, or other cancer-directed treatment. For chemotherapy-related nausea and vomiting, approved cannabinoid medicines may be considered when standard therapies are insufficient. For pain, appetite loss, sleep disturbance, or anxiety, the potential benefits are more uncertain and should be weighed against risks on an individual basis.